The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback